PIK3CA

News

Celcuity eyes big market opportunity after breast cancer win

Celcuity shares rocket on a big win for its lead drug gedatolisib in advanced breast cancer, catapulting its value to almost $1.4 billion.

News

T-cells attacking cancer cell illustration of microscopic photos

Novartis scores first approval for PIK3CA breast cancer drug

The FDA has approved Novartis’ breast cancer drug Piqray (alpelisib), making it the first marketed treatment targeting the PIK3CA mutation in this disease.

News

ESC26: Isomab safety evidence on blood vessel growth for CAD

Isomab has presented landmark safety data at ESC, clearing the path for next-generation therapies to promote blood vessel growth in CAD.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Editor's Picks